<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699645</url>
  </required_header>
  <id_info>
    <org_study_id>TRIDENT-1103886</org_study_id>
    <nct_id>NCT02699645</nct_id>
  </id_info>
  <brief_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial</brief_title>
  <acronym>TRIDENT</acronym>
  <official_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigator initiated and conducted, multicentre, international, double-blinded,
      placebo-controlled, parallel-group, randomised controlled trial to determine the effects of a
      fixed low-dose combination blood pressure lowering pill (&quot;Triple Pill&quot;) on top of standard of
      care on blood pressure control and on time to first occurrence of recurrent stroke in
      patients with a history of acute intracerebral haemorrhage (TRIDENT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke,
      accounting for at least 10% of the 20 million new strokes that occur globally each year.
      Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events.

      While there is strong evidence that this risk can be reduced by lowering the blood pressure
      (BP) of patients after ICH, many patients with ICH do not receive blood pressure lowering
      long-term unless the blood pressure levels are particularly high, and many do not receive BP
      combination therapy.

      The aim of this study is to assess the safety and efficacy of a combination of fixed low-dose
      generic BP lowering agents as a &quot;Triple Pill&quot; strategy on top of standard of care for the
      prevention of recurrent stroke in patients with a history of ICH and high normal or low grade
      hypertension in a large-scale, international, double-blind, placebo-controlled, randomised
      controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Stroke</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Time to first occurrence of recurrent stroke, whether ischaemic or haemorrhagic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent ICH</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Time to first occurrence of recurrent ICH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic Stroke</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Time to first occurrence of ischaemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal or disabling stroke</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Time to first occurrence of fatal or disabling stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Major adverse cardiovascular events - CV death, non-fatal MI or non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Physical function as assessed by smRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Change in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL according to the EQ-5D-3L</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Health-related quality of life according to the European Quality of Life 5-Dimensional Assessment, 3-Level version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Overall defined by standard cut-points on the Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment Supplement</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Overall defined by standard cut-points with Brief Memory and Executive Test (BMET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>Average of 3 years</time_frame>
    <description>Pill counts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4200</enrollment>
  <condition>Acute Intracerebral Haemorrhage (ICH)</condition>
  <arm_group>
    <arm_group_label>Triple Pill (active treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received via blinded study capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg</intervention_name>
    <description>1 capsule taken orally once daily for 36 months</description>
    <arm_group_label>Triple Pill (active treatment)</arm_group_label>
    <other_name>Triple Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule taken orally once daily for 36 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (â‰¥18 years) with a history of up to 6 months after symptom onset of primary ICH
             that is confirmed by imaging (copy of the brain imaging report to be submitted to the
             CCC labelled with study ID and with personal identifiers removed)

          -  Clinically stable, as judged by investigator

          -  Two resting SBP levels measured 5 minutes apart in the range 130-160mmHg recorded in a
             seated position (Australian Heart Foundation Guidelines: Appendix 19.1). (Patients
             with higher SBP can be included if considered by attending clinician that management
             is consistent with local standards of clinical practice)

          -  Geographical proximity to the recruiting hospital and/or follow-up medical clinic site
             to allow ready access for in-person clinic visits during follow-up

          -  No clear contraindication to any of the study treatments

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Taking an ACE-I that cannot be switched to any of the following alternatives (see
             Appendix 19.2):

               -  telmisartan 20 or 40mg, amlodipine 2.5 or 5mg, indapamide 1.25 or 2.5mg, or

               -  an equivalent class (ARB, CCB or thiazide-like diuretic), or

               -  a beta-blocker

          -  Contraindication to any of the study medications, in the context of currently
             prescribed BP-lowering medication

          -  Unable to complete the study procedures and/or follow-up

          -  Females of child bearing age and capability, who are pregnant or breast-feeding, or
             those not using adequate birth control

          -  Significant hyperkalaemia and/or hyponatremia, in the opinion of the responsible
             physician

          -  Estimated glomerular filtration rate (eGFR) &lt;30 mL/min

          -  Severe hepatic impairment (ALT or AST &gt;3x the ULN)

          -  Any other condition that in the opinion of the responsible physician investigator
             renders the patient unsuitable for the study (e.g. severe disability [i.e. smRS of
             4-5] or significant memory or behavioural disorder)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grace Balicki</last_name>
    <phone>+61 2 8052 4811</phone>
    <email>gbalicki@georgeinstitute.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Freed</last_name>
    <phone>+61 2 8052 4522</phone>
    <email>rfreed@georgeinstitute.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Calvary Public Hospital</name>
      <address>
        <city>Bruce</city>
        <state>Australian Capital Territory</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roann Cheng</last_name>
      <email>Roann.Cheng@calvary-act.com.au</email>
    </contact>
    <investigator>
      <last_name>Ronak Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shabeel Askar</last_name>
      <email>Shabeel.Askar@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Dennis Cordato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Parrey</last_name>
      <email>kim.parrey@ncahs.health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Ray</last_name>
      <email>elizabeth.ray@sswahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Candice Delcourt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wade Skoien</last_name>
      <email>wade.skoien@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Floris Schreuder</last_name>
      <email>floris.schreuder@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colombo North Teaching Hospital</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Udaya Ranawake</last_name>
    </contact>
    <investigator>
      <last_name>Udaya Ranawake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalubowila (Colombo South) Teaching Hospital</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjuna Fernando</last_name>
    </contact>
    <investigator>
      <last_name>Arjuna Fernando</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital of Sri Lanka</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bimsara Senanayake</last_name>
    </contact>
    <investigator>
      <last_name>Bimsara Senanayake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital Kurunegala</name>
      <address>
        <city>Kurunegala</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dharshana Sirisena</last_name>
    </contact>
    <investigator>
      <last_name>Dharshana Sirisena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sri Jayewardenepura General Hospital</name>
      <address>
        <city>Nugegoda</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harsha Gunasekara</last_name>
    </contact>
    <investigator>
      <last_name>Harsha Gunasekara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peradeniya Teaching Hospital</name>
      <address>
        <city>Peradeniya</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadie Ratnayake</last_name>
    </contact>
    <investigator>
      <last_name>Nadie Ratnayake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>Sri Lanka</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

